Related Experiment Video
Updated: Jun 24, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.6K
Antiarrhythmic effects of metformin
Lorraine Mascarenhas1, Michael Downey2, Gregory Schwartz3
1Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Heart Rhythm O2
|June 6, 2024
Summary
Metformin, a common diabetes drug, may help prevent atrial fibrillation (AF) and other heart arrhythmias. Research suggests it improves risk factors and is linked to reduced AF incidence in diabetic patients.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atrial fibrillation (AF) is a prevalent condition linked to serious health issues like stroke and heart failure.
- Current AF prevention medications have limited effectiveness and notable side effects.
- Ventricular arrhythmias, though less common, can lead to sudden cardiac death.
Purpose of the Study:
- To review existing evidence on metformin's association with cardiac arrhythmias.
- To explore the potential antiarrhythmic mechanisms of metformin.
- To assess metformin's suitability for repurposing in arrhythmia prevention.
Main Methods:
- Review of experimental studies on metformin's effects on AF and ventricular arrhythmia risk factors.
- Analysis of large clinical observational studies examining metformin use and AF risk in diabetes mellitus patients.
Main Results:
- Experimental data indicate metformin improves metabolic, electrical, and histologic factors relevant to arrhythmias.
- Observational studies suggest a correlation between metformin use and a lower incidence of AF in individuals with diabetes mellitus.
- Metformin demonstrates potential antiarrhythmic properties.
Conclusions:
- Metformin shows promise as a potential therapeutic agent for preventing cardiac arrhythmias.
- Repurposing metformin, a safe and affordable medication, could significantly benefit public health by offering a new strategy for arrhythmia prevention.
Keywords:
ArrhythmiaAtrial fibrillationMetforminPrediabetesVentricular fibrillationVentricular tachycardiaMore Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
736
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
736
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
969
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
969
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823